Table Of ContentCLINICS IN
S GERIATRIC
MEDICINE
Clin Geriatr Med 19 (2003) 857—873
Cumulative Index 2003
Volume 19
February RESPIRATORY DISEASE IN THE ELDERLY, pages 1-244
May OSTEOPOROSIS, pages 245-462
August GERIATRIC SEXUALITY, pages 463-662
November GERIATRIC MENTAL HEALTH, pages 663-873
Note: Page numbers of article titles are in boldface type.
A inpatient versus residential treatment of,
Absorptiometry, prediction of hip fracture 153- 154
using, 286, 287 prevalence of, 744-746
i self-help group meetings in, 756—757
Advanced care planning, in chronic obstructive treatment of, 751—753
pulmonary disease, 226 :
in congestive heart failure, 226 Alcohol use disorders test, 752
patient preferences and, 227
Alcoholic patients, alcohol-related problems in,
Affective disorders, antipsychotics for, 707 diagnosis of, 750
psychotic symptoms in, 707 effects of alcohol ve ie ¥ bade
patterns of problem drinking in,
Age, as factor in risk for osteoporosis, 747-748
246-247
Alcoholics Anonymous, 756—757
Aging, bone remodeling and, 263-267 a ; J
libido with, 467 Alendronate, clinical trials of, 399-400
current use of, 401
AIDS and HIV. See HIV and AIDS. parathyroid hormone and, in
osteoporosis, 428
AIDS-related dementia, and Alzheimer’s tolerability and side effects of, 401
disease, features of, 651
: ' eles Alprazolam, 710
Alcohol, intake of. See also Drinking.
benefits and risks of, 331 Alzheimer’s disease, 769-770
by older adults, 684-687 accelerated brain aging and, 623-624
moderate, as protective, 685 and AIDS-related dementia, features
sexual function and, 560 of, 651
4 and other dementias, 763—776
Alcohol abuse/dependence, in older adults, peat aL Ng
; : conditions mimicking, 766
detection of, 685-687 ae saat eae
rae Mae depression of, diagnostic criteria for, 808
incidence of, 685—687 spe pg S
risk of, hormone replacement therapy
Alcohol dependence, background of, 744 and, 623, 624
collateral medical and psychiatric treatment of deficits in, 766—767
treatment in, 754—755 ‘ ’ - ih ia
diagnosis of, and treatment of, scar Sanaehy hine sr Medicine
743-761 patient criteria, 753, 75
barriers to, 745-746 Anal eroticism, 634—635
individual and group therapy in,
755-756 Androgens, in erectile dysfunction, 534
0749-0690/03/$ — see front matter © 2003 Elsevier Inc. All rights reserved.
doi: 10.1016/S0749-0690(03 )00056-9
858 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
Andropause, 507-528 laboratory investigations of, 730
assays for, 520 management of, 730—733
behavioral effects of, 607 pharmacologic treatment in, 730-733
pathophysiology of, 509-510 psychologic treatments in, 733-735
screenings for, for primary care settings,
Andropause questionnaires, 518-520 729-730
Anesthesia, as risk factor in pulmonary selective serotonin reuptake inhibitors
surgery, 45—46 in, 731
serotonin/norepinephrine reuptake
Angiography, pulmonary, to diagnose inhibitors in, 732
pulmonary embolism, 164 symptoms of, 722
Ankle, fractures of, antiglideplate and, Anxiety disorder(s), 677-681
449, 450
antidepressants in, 699
Antibiotics, in dementia, 849 characteristics of, 723-726
comorbidity of, 681
Anticholinergic toxicity, 713 depression and, 672
Anticonvulsants, 708—710 frequency of, 722
electroconvulsive therapy and, 833 generalized, 724
sexual function and, 560 in older adults, 721-741
prevalence of, 677—678
Antidepressants, 698 —7 03
adverse effects of, 700 Anxiolytic drugs, sexual function and, 556
in bipolar disorder, 794 Apathy, diagnostic criteria for, 807
in dementia, 814
in special elderly populations, 699-700 Apnea index, 183
plus psychotherapy, 698
Apomorphine, in erectile dysfunction, 534
sexual function and, 555
tricyclic, 700-701 Apomorphine SL, in erectile dysfunction, 479
Anti-estrogens, selective, 373-381 Aripiprazole, 706—707
in dementia, 816
Antiglideplate, fractures of ankle and, 449, 450
Arterial blood gas values, in pulmonary
Antihypertensive drugs, sexual function and, embolism, 160
556-557
Arthritis, sexual dysfunction and, 567-568
Anti-inflammatory agents, in asthma, 66—68
Asthma, abnormal neurogenic influences in, 59
Antipsychotics, 703 —707
airway obstruction in, 60
adverse drug reactions with, 704
airway responsiveness in, 59-60
adverse effects of, 703 atopic, 60-61
and hyperlipidemia, 705
bronchial hyperresponsiveness in, 59
and weight gain, 704—705
clinical characterisitcs of, 63-64
for affective disorders, 707
clinical outcome and prognosis in, 71
hyperprolactinemia due to, 703-704 definition of, 57
in bipolar disorder, 793
epidemiology of, 62—63
movement disorders induced by, histopathologic findings in, 58-59
703 —704
in elderly, 57-75
new-onset diabetes and, 705
fixed airflow obstruction in, 64
Anxiety, and medical illness, 726—727 inhalation therapy in, 70—71
as adaptive emotional reaction, 721 —722 non-atopic, 61 —62
assessment of, with rating scales, pathophysiology of, 58—62
728-729 postoperative pulmonary complications
atypical neuroleptics in, 733 in, 42
azapirones, 733 treatment of, 65—66
benzodiazepines in, 732 by severity of disease, 67
clinical evaluation of, 728—730 medication for, 66—70
collaborative models of care in, 735—736 Autonepiophilia, 634
comorbid, and depression, 727-728
end-of-life care in, 844—845 Autonomic system, during normal aging of
in dementia, 680 respiratory system, |1—12
Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
B metabolism of, pathophysiology of
Back, exercise to strengthen, 341 estrogen deficiency on, 364
extensor strength, 340, 343 testosterone and, 514
strength of, by age, 347, 352
Bone density, measurements of, in male
Back supports (Posture Training Support), osteoporosis, 314
in osteoporosis, 353-354, 355, 358,
Bone loss, in women, 263-264
359, 360
pathophysiology of, 259-270
Bacterial vaginosis, 641 —642
Bone markers, effects of salmon nasal spray
Balance, changes in, computerized dynamic calcitonin on, 389
posturography to assess, 349
Bone mass, calcium and, 326
Behavioral emergencies, management of, 712 effects of withdrawal of parathyroid
hormone on, 428—429
Benzodiazepines, 710 exercises to improve, 341
electroconvulsive therapy and, 832 measurements of, 281—297
devices for, WHO criteria for,
Binge drinking, 748—750
282-283, 284
Biphosphonates, in osteoporosis, 499 monitoring of, 289-294
vitamin D and, 327
Bipolar disorder, 786—794
antidepressants in, 794 Bone mineral density, 245, 246
antipsychotics in, 793 cigarette smoking and, 248, 251
carbamazepine in, 793 effect of hormone replacement therapy
demographic factors in, 788—789 on, 364—365, 368
differential diagnosis of, 789-790 effects of calcitonin on, 384
lithium in, 791-792 effects of salmon nasal spray calcitonin
nonpharmacologic treatment in, 794 on, 385—387
presentation of, 787—788 fracture risk and, 250
prognosis in, 789 protein intake and, 327-328
treatment of, 790-794
Bone remodeling, 259-262
valproate in, 792—793
aging and, 263-267
Bipolar disorders, antidepressants in, 699 as systematic process, 262
function of, 260—261
Bisphosphonate(s), 397-416 phases of, 259, 260
binding to bone, 397
combined with other agents, 408 Boron, effect on bone, 331
compared, for tolerability, 407-408
Brace, to prevent lumbar and thoracic flexion,
efficacy of, compared, 407 356, 359
for treatment of osteoporosis, 397-416
general side effects and toxicity of, 408 Brain, space-occupying lesions of, electrocon-
in development, 406 vulsive therapy in, 831
mechanism of action of, 398-399
Brain aging, accelerated, and Alzheimer’s
structure(s) of, 397, 398
disease, 623-624
uses of, 397
Brain tumors, electroconvulsive therapy
a-Blockers, sexual function and, 558
in, 831
8-Blockers, sexual function and, 558, 559
Breast cancer, altered expression of, in
Body mass index, and back strength, by age, estrogen deficiency, 621-623
347, 352 raloxifene in, 376—377
by age, 347 sexual function and, 468
tamoxifen in, 373, 374—375, 377
Bone, cancellous, changes in remodeling of,
with age, 263-266 Breathing, sleep-disordered, 183-185
cortical, changes in remodeling of, with in elderly patients, 184—185
age, 266—267
Breathlessness. See Dyspnea.
density of, impact of estrogen on, 365
long, fractures of, in osteoporosis, ortho- Bronchial obstruction, at end of life, manage-
pedic management of, 437-459 ment of, 229
860 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
Bronchodilators, in asthma, 68—70 Candidiasis, vulvovaginal, 642-643
in dyspnea, 231-232
Capgras syndrome, 805
Bronchoscopy, in lung cancer,
Carbamazepine, 709
Bupropion, in depression, 702 in bipolar disorder, 793
Buspirone, 710—711 Carcinomatous lymphangitis, at end of life,
management of, 231
Cc Cardiac disease, suspected, dyspnea in, 28
Cardiovascular disease, accelerated, in
Caffeine. intake of, and calcium balance, 329
estrogen deficiency, 618-619
CAGE questionnaire, 750 electroconvulsive therapy in, 831
in postmenopausal period, 495—496
Calcitonin, 383-396
sexual dysfunction and, 569
analgesic effects of, 390-391
testosterone and, 514—515
effects on bone mineral density, 384
effects on fracture, 384 Cardiovascular health, of older
in combination therapy, 392 homosexuals, 589
glucocorticoid-induced
osteoporosis, 390 Care planning. See Advanced care planning.
osteoporosis in older woman, treat- Caregiving, changing roles and, 601
ment of, 383—384
injectable, in postmenopausal osteoporo- Central nervous system, disorders of, restric-
sis, 384 tive pulmonary syndrome in, 193
nasal, in older women, administration efferent impulse of, dyspnea and, 23
and side effects of, 391 integration/processing in, dyspnea
resistance to, 391 and, 22
role of, in treatment of postmenopausal
Cerebrovascular accidents, sexual dysfunction
osteoporosis, 392 —393
and, 568
salmon nasal spray, effect on fracture
reduction, 389 Cerebrovascular disease, as cause of manic
effects on bone markers, 389 symptoms, 790
effects on fracture, 387-388 electroconvulsive therapy in, 831
in men with idiopathic osteoporo- impact on mood disorders, 778-779
sis, 389-390
Cervicitis, 639-640, 641
in postmenopausal osteoporosis,
gonococcal and chlamydial, 639, 641
384-389
Chancroid, 644—645
Calcium, and bone mass, 326
as essential nutrient, 323 Chemotherapeutic agents, sexual function
balance of, and cafeine intake, 329 and, 560
osteoporosis and, 497-498
daily dietary intake of, estimation of, 324 Chest radiograph, to diagnose pulmonary
daily intake of, 325-326 embolism, 159-160
excretion of, salt and, 328 Chlamydial cervicitis, 639, 641
in calcium supplements, 324
mean fractional absorption of, 323 Cholinesterase inhibitors, 711
recommended intake of, 323-324 in dementia, 817
vitamin D, and fractures, 327 Chronic obstructive pulmonary disease, 40—42
and nutrition, in elderly adults, advanced care planning in, 226
323-337 mechanical ventilation in, 216
Cancer, and older homosexuals, 588 —5 89 respiratory failure in, 207—208
colorectal, accelerated, in estrogen defi- Citalopram, 698
ciency, 621
erectile dysfunction in, 532 Clodronate, clinical trials of, 404
of breast, altered expression of, in estro- current use of, 405
gen deficiency, 621 —623
Clomipramine, effect on sexual function, 554
sexual function and, 468
sexual dysfunction and, 566—567 Clonazepam, 710
Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
Clozapine, 705, 712—713 clinical features and pathology of,
in dementia, 816 765-766
clinical history of, 764
Cognition, in perimenopausal syndrome,
488—489 electroconvulsive therapy in, 818
end-of-life care in, 848-851
Cognitive impairment, 672-677 etiology of, 810-812
incidence of, 673 issues in diagnosis and treatment of,
sexuality and, 602 763-764
neurotransmitter correlates in, 768—769
Cognitive problems, in men, 609-610 Parkinson, 771—772
Colorectal cancer, accelerated, in estrogen prevalence of, 672, 673, 674, 676
deficiency, 621 risk factors for, 673
stages of, 848-849
Computed tomography, in lung cancer, vascular, 770—771
141-142 weight loss and aspiration pneumonia
spiral, to diagnose pulmonary embolism, in, 849
163-164 WHO definition of, 764
with behavioral and psychologic
Connective tissue, disorders of, and
symptoms, 799-825
osteoporosis, 306, 309
agitation in, 802, 803
“Cortical steal” phenomenon, 429 anxiety in, 806
apathy in, 806-807
Corticosteroids, in dyspnea, 232 caregivers in, 818
clinical symptoms of, 802-804
Cough, at end of life, management of, 235
delusions and hallucinations in,
pathophysiology of, 234
803-804
Cough reflex, during normal aging of depression in, 807—808
respiratory system, 9 development of term, 800-801
economics of, 818—819
Coughing, assisted, in restrictive pulmonary environment and, 809-810
syndrome, 199-200, 201 pharmacologic interventions in,
812-818
Counseling, for patients with medical
psychosis in, 812
conditions, 600—601
psychotherapies in, 810
in erectile dysfunction, 535
sleep disturbances in, 802—803
prevention, 597, 598
wandering, 808-809
with Lewy bodies, 771
D Depression, and anxiety disorders, 672
as psychologic outcome of osteoporosis,
D-dimer concentration, in pulmonary 273-274
embolism, 160-161 dysthymic, 779
Delirium, costs of, 847 end-of-life care in, 842—844
diagnosis of, 846 erectile dysfunction in, 532
end-of-life care in, 845—848 executive dysfunction in, 784
medications associated with development in ischemic heart disease, antidepressants
of, 847 in, 699
prevalence and incidence of, 846 late life, assessment and diagnosis of,
treatment of, 847-848 777-786
biological risk factors for,
Dementia(s), 672—677 781-783
adverse outcomes of, 677 mortality associated with, 781
AIDS-related, and Alzheimer’s disease, psychosocial risk factors for, 783
features of, 651 risk factors for, 781 —783
AiZiieimer’s disease and, 763—776 subsymdromal, 779
antibiotics in, 849 treatment of, 783—785
antidepressants in, 814 palliative care in, 843—844
anxiety in, 680 poststroke, antidepressants in, 699
behavioral symptoms in, 849-850 psychotic symptoms and, 684
cholinergic deficits in, 767-768 treatment of, in primary care, 785
862 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
Dextroamphetamine, in depression, 702 mechanisms of, 20-21
mechanoreceptors and, 21 —22
Diabetes, electroconvulsive therapy in,
831-832 pathophysiology of, 227-228
erectile dysfunction in, 531 pharmacologic treatment of, at end of
life, 231-234
new-onset, antipsychotics and, 705
sexual dysfunction and, 568—569 prevalence of, in elderly, 19-20
sexual function and, 468 psychotropic medications in, 31
ratings of, during exercise and aging, 24
Digoxin, sexual function and, 559 sensation of, receptor sites in, 2] —22
treatment of, 29-31
Disease, sexuality and, 563-573
upper extremity resistance training in, 30
Diuretics, electroconvulsive therapy and, 833 ventilatory muuscle training in, 30—31
sexual function and, 557
Donepezil, in dementia, 817
Drinking, binge, 748—750 E
and concomitant drug use, 750 Echocardiography, to diagnose pulmonary
continuous, versus intermittent, 743 embolism, 162
Drug(s), adverse reactions to, antipsychotics Ejaculation, disorders of, 531
and, 704—705
as cause of erectile dysfunction, 477 Elderly. See Older adults.
oral, in erectile dysfunction, 533-534 Electrocardiogram, in pulmonary
Drug-drug interactions, 712, 713 embolism, 160
Drug therapy, in osteoporosis, 498-499 Electroconvulsive therapy, adverse effects of,
828, 835-836
DSM criteria, to assess mood disorders, anesthetic agents for, 834—835
777-779 caffeine in, 835
cardiovascular agents for, 834
Duloxetine, 702
cardiovascular complications of, 835
Dysphoria, testosterone and, in men, 608 —609 continuation, 837
contraindications to, 830
Dyspnea, alternative medicine modalities
electrode placement for, 833-834
in, 233
evaluation prior to, 830
assessment of, history and symptom
frequency and number of treatments with,
scales in, 228 836-837
physical examination and diagnos-
future directions in, 838
tic testing in, 228-229 headache in, 836
at end of life, 225 in dementia, 818
breathing training in, 29
elderly, 827-840
causes of, management considerations major depression, 828— 829
and, 229-231 mania, 829
characteristics of, 25, 26
medical conditions, 830
chemoreceptors and, 21 schizophrenia, 829
chronic, evaluation of, physical findings indications for, 826
for, 25—26
maintenance, 837
unexplained, 28—29 mechanism of action of, 827-828
coping stategies in, 29— 30
muscle relaxants in, 835
definition of, 19, 225
postictal delirium in, 836
during normal aging of respiratory
premedications for, 834
system, 8—9
prolonged apnea in, 835
efferent impulse of CNS and, 23
prolonged seizures with, 835
elderly patient with, approach to, 24—28
risks of use of, 831—832
evaluation of, in older adults, 19-33
exercise training/reconditioning in, 30 Electrolyte disturbances, electroconvulsive
in suspected cardiac disease, 28 therapy in, 832
in suspected respiratory disease, 28
Embolism, pulmonary. See
integration/processing in CNS and, 22
Pulmonary embolism.
intensity of, lung involvement and anxi-
ety and, 225-226 Emphysema, senile, 4
Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 863
End-of-life, management of respiratory Exercise(s), and compression fractures, 352,
symptoms at, 225-238 354, 358
and osteoporosis, 352—354
End-of-life care, caregiver issues at, 851—852 dyspnea rating during, 24
in anxiety, 844—845 nonstrenuous, in severe osteoporosis,
in delirium, 845—848 350-351
dementia, 848-851 program of, in osteoporosis, physical
depression, 842—844 examination prior to, 356—360
geriatric psychiatry, 841-856 to improve bone mass, 341
psychologic considerations in, 841—842 to strengthen back, 341
Endocrine disorders, osteoporosis and, Exercise capacity, during normal aging of
304-306 respiratory system, 12-13
Endotracheal intubation, ventilator-associated Exhibitionism, as paraphilia, 631 —632
pneumonia and, 217—218
Epilepsy, electroconvulsive therapy in, 838
Erectile dysfunction, 529-538 F
and disease, 565—566
causes of, in older men, 476—477 Falls, as risk factor for fracture, 251
definition of, 539
Family history, as risk for fractures, 251
epidemiologic aspects and prevalence of, of patients with osteoporosis, 302
529-530
risk for osteoporosis and, 248
etiology and treatment of, 539-551
etiology of, 541, 543, 544 Femoral neck fractures, 442—444
evaluation and treatment of,
incidence of, 539 Femur, distal, supracondylar fractures of,
medical conditions associated with, 531, 446-448
Fetishes, and paraphilia, 633-634
study of, methods in, 540
results of, 540—543 Fist fornication, 635
treatment of, 533 543
Fluoride, dietary sources of, 331
Frection, neural pathways controlling, 474 excess ingestion of, 331
Eroticism, anal, 634—635 Follicle stimulating hormone, menopause
and, 464
Estrogen, deficiency of, following menopause,
Food and Drug Administration, monitoring of
464-465
bone mass measurements and, 289
impact on bone density, 365
parathyroid hormone and, in Food groups, effect on bone health, 332
osteoporosis, 425—426, 427
progestogens with, effect on bone Fracture(s). See also specific sites and types of
density, 365 fractures.
use in older women, 617-627 as consequence of bone loss, 341
compression, exercise and, 352,
Estrogen deficiency, pathophysiology of, on in osteoporosis, 343
bone metabolism, 364 effects of calcitonin on, 384
effects of salmon nasal spray calcitonin
Estrogen deficiency state, clinical consequen- on, 387—388
ces of, 617—624 epidemiology of, 249-250
Estrogen preparations, vaginal, 465-466 falls as risk factor for, 251
family history as risk for, 251
Estrogen/progestin hormone therapy, study fragility, consequences of, 249—250
of, 495 risk for future fractures and, 301
healing of, and stability of, augmentation
Estrogen-receptor modulators, selective,
of, 439-442, 443
373-381
intertrochanteric, and sliding hip screw,
Etidronate, clinical trials of, 403—404 444-446, 447
current use of, 404 location of, diagnostic implications of,
tolerability and side effects of, 404 301-302
Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
management of, clinical strategies in, Genital ulcer disease, 643
442-453
Geriatric Depression Scale (GDS), 665
in osteoporosis, 438—439, 440, 441
postoperative care in, Geriatric Mental State Schedule
453-456 (AGECAT), 665
of ankle, antiglideplate and, 449, 450
of hip. See Hip, fractures of. Glucocorticoid-induced osteoporosis, calcito-
of proximal humerus, tension band fix- nin in, 390
ation in, 450—451, 452 parathyroid hormone in, 426
of spine, osteoporosis-related, sedatives Gonococcal cervicitis, 639, 641
and physical therapy in, 346
of wrist, management of, 451 —452 Gonococcal infections, treatment for, 638, 639
osteoporosis-related, 437
personal history of, and risk for,
250-251
prevention of, 339 H
probability of, 249 Health care, avoidance of, by
rates of, across ethnicities, NORA data homosexuals, 591]
on, 282, 283
Health care providers, discussion of sexuality
reduction of, effects of salmon nasal
by, 596
spray calcitonin on, 389
health care of homosexuals and,
risk factors for, 250—252
risk of, NORA dataset for, 282 590—591
prediction of, NORA studies of, Heart failure, congestive, advanced care plan-
286-289 ning in, 226
supracondylar, of distal femur, 446—448 at end of life, management of, 230
tibial plateau, lateral, and rafter plate,
448 —449 Herpes, genital, 643-644
vertebral, and long bone, in osteoporosis, treatment of, 644
orthopedic management of, Hiccups, at end of life, management of,
437-459 235-236
in osteoporosis, 452 —453, pathophysiology of, 234
454-455
prevention of, hormone replace- Hip, fracture(s) of, 363
ment therapy in, 366-368 complications of, 344, 345
vitamin D, and calcium, 327 diagnosis of, 344
wedging and compression, osteoporosis- missed, 344
related, 342, 343 osteoporotic, 496
prevention of, hormone replacement
Fregoli syndrome, 806 therapy in, 366-367
Frontotemporal dementia, 772 risk factors for, 301
risk of, fractures contributing to,
344-345
G HIV and AIDS, in older adult, 647-652
Galantamine, in dementia, 817 diagnosis of, 648—651
management of, 651 —652
Gas exchange, during normal aging of respira- risk factors for, 647—648
tory system, 9—11 in older homosexuals, 589
Gastrointestinal disorders, in osteoporosis, Home-based mechanical ventilation, 220
307-308
Homophobia, as health care barrier to homo-
Gastrointestinal medications, sexual function sexuals, 590
and, 559-560
Homosexual(s), older, 587-593
Gender, as factor in risk for osteoporosis, 247 behavioral health and, 588
cancer and, 588—589
Generalized anxiety disorder, prevalence of,
cardiovascular health and, 589
677, 680
community support for, 592
Genital herpes, 643-644 financial rights of, 591
treatment of, 644 health care of, barriers to, 590—591
Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
health studies and, 587—589
HIV and AIDS in, 589 Incontinence, sexual dysfunction and, 566
living situation of, 591
mental health and, 588 infantilism, paraphilic, 634
social support for, 592 Infiltrative disorders, in osteoporosis, 307
unique concerns of, 602
Insomnia, 181—183
Hormonal changes, with menopause, 464—465 Intermittent positive pressure ventilation, lip
seal for, 195, 196
Hormone replacement therapy, 469
noninvasive, 198—199, 200
adverse effects of, 368-369
benefit of, for elderly postmenopausal Internal fixation, in fractures in osteoporosis,
woman, 624 437, 438
duration of, and impact of withdrawal Intertrochanteric fractures, and sliding hip
of, 368 screw, 444—446, 447
effect on bone mineral density,
364-365, 368 Intracavernosal injection therapy, in erectile
effect on incidence of breast cancer, 6 dysfunction, 479-480
21-622 Ischemic heart disease, depression in, antide-
efficacy of, 364-368 pressants in, 699
for prevention of fractures of hip,
366-367
for prevention of vertebral fractures, K
366-368
Kidney disease, psychopharmacology in,
in perimenopausal syndrome, 491—492 713-714
in postmenopausal osteoporosis,
363-372 Knee, extensor strength, 340
risk of Alzheimer’s disease and, 623, 624
Kyphosis, in osteoporosis, 343-344
Women’s Health Initiative study of,
= 369-370
Hot flashes, in perimenopausal syndrome, L
486-487 Laboratory evaluation, in osteoporosis,
treatment of, in perimenopausal 309-311
syndrome, 492—493
Lamotrigine, 710
Humerus, proximal, fractures of, tension band L-dopa/carbidopa, electroconvulsive therapy
fixation in, 450—451, 452 and, 833
Hyperlipidemia, antipsychotics and, 705 Libido, testosterone and, 467, 511
with age, 467
Hyperparathyroidism, primary, parathyroid
hormone therapy and, 418—420 Life, quality of, and general versus disease-
targeted quality of life scales, 277
Hypertension, erectile dysfunction in, and osteoporosis-targeted quality of
531-532, 545 life scales, 276-277
osteoporosis and, 275—276
Hyperthyroidism, electroconvulsive therapy future directions in, 277—278
in, 832
psychosocial outcomes and
interventions for,
Hypnotics, 711 271-280
Hypoglycemic agents, electroconvulsive Limbs, periodic movements of, during
therapy and, 833 sleep, 186
Hypogonadism, erectile dysfunction in, Lipid-lowering agents, sexual function
532-533, 541, 543-545 and, 559
Hypothalamic-pituitary-gonadal axis, systemic Lithium, 707—708
diseases and, 564 electroconvulsive therapy and, 833
in bipolar disorder, 791 —792
Hypothalamic-pituitary-testicular axis, with precautions in use of, 791—792
aging, 510 side effects of, 708
866 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873
Liver disease, psychopharmacology in, 713 home-based, 220
in chronic obstructive pulmonary disease,
Longitudinal Aging Study (Amsterdam),
208, 216
779-780
in respiratory failure, 205
Lung(s), cancer of, cell types of, 140
diagnosis of, and screening for, Medical illness, anxiety and, 726-727
sexual function and, 467-469
140-145
in elderly, 139-155 Medication asistance programs, pharmaceutical
staging of, 145-149 company-sponsored, 714
treatment of, in elderly, 149-152
Medications. See also Drug(s).
chronic obstructive disease of, 40—42
and sexual function, 553-562, 601
embolism of. See Pulmonary embolism.
associated with osteoporosis, 306, 309
function of, aging and, 23—24
for asthma therapy, 66—70
in relation to aging, 191
function testing and, 48—49 Men, disorders of sexual function in, 473—482
impairment of, definition of, 189-191
Menopause, 483-504
multifaactorial risk indices and, 46—48
average age of, 484
postoperative complications of, age as
clinical approach to, 485
risk factor for, 36—39
estrogen deficiency following, 464—465
cigarette use and, 39-40
follicle stimulating hormone and, 464
genral health status and, 44
hormonal changes with, 464—465
in asthma, 42 induced, 483
obesity and, 42—44
natural, 483
patient-related risk factors for,
pathophysiology of, 484-485
39-44
symptoms of, impacting sexual function,
risk factors for, 49, 50
465 —467
preoperative assessment of, in older
transition to, 483
adult, 35-55
procedure-related risk factors and, Mental disorders, implicetions of, for geriatric
anesthesia as, 45—46 medicine, 688
neuromuscular blocking agent late-life, epidemiology of, 663-696
and, 46 prevalence of, 664—668
surgery and, 45
Methylphenidate, in depression, 702
Lung scanning, ventilation-perfusion, to diag-
nose pulmonary embolism, 162-163 Mini-Mental State Examination (MMSE), 665
Lung volumes, during normal aging of respi- Mirtazapine, in depression, 702
ratory system, 6—7
Mood and sleep disorders, treatment of, in
Lymphangitis, carcinomatous, at end of life, perimenopausal syndrome, 494
management of, 231 Mood disorders, categories of, 779
in older populations, prevalence of,
666-667, 668-672
M
in perimenopausal syndrome, 489-490
Magnesium, recommended intake of, 330 late life, 777-797
Magnetic resonance imaging, to diagnose Mood stabilizers, 707 —708
pulmonary embolism, 161-162
Movement disorders, induced by antipsy-
Major depressive disorder, 779
chotics, 703-704
Malignancies, in osteoporosis, 307
Muscle(s), bulbar, weakness of, causes of, 190
Mania, electroconvulsive therapy in, 829
Muscle fibers, reduction of, in aging, 352
Manic episode(s), criteria for, 787
differential diagnosis of, 789-790 Muscle loss, osteoporosis and, 339-341
MAOIs, in depression, 702 Muscular dysfunction, elderly patients with,
Masturbation, and paraphilia, 632 pulmonary physical medicine interven-
tions for, 189-204
Mechanical ventilation, acute respiratory dis-
tress syndrome and, 209, 211 Musculoskeletal disorders, sexual function
costs of, in elderly patients, 216—217 and, 468
